Starting point
In June 2021, OPKO announced a license agreement with Nicoya Therapeutics covering Greater China, including mainland China, Hong Kong, Macau and Taiwan.
Long-term collaboration
The framework connects regional development, regulatory progress and commercialization preparation, forming the basis for later milestones. Local status should always be checked against formal regulatory and company announcements.
Continued collaboration
The parties will continue regional development and commercialization work under the existing framework. Local status should be checked against regulatory and company announcements.